In Vitro Radiosensitization Of Human Cervical Cancer Hela Cells With Iron Oxide- Titanium Dioxide Core-Shell Nanoparticles Conjugated With 3,4-Dihydroxyphenylacetic Acid (Dopac).

Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Cervical cancer is resistant to current surgical, chemo- and radiotherapy interventions and represents a virtually incurable tumor. In this study, we explored titanium dioxide core-shell nanocomposites conjugated with DOPAC (DOPAC-NCs) as radiosensitizers. Radioresistant human carcinoma cervical HeLa cell cultures were treated with or without of increasing concentrations of DOPAC-NCs (5-20 nM) prior to irradiation. One hour later, cells were irradiated with a single dose of gamma radiation (5 Gy, 10 Gy, or 15 Gy). Seventy-two hours following radiation treatment, cell proliferation/viability was assessed by MTS assay. Sham-irradiated cells were served as a control. We have found that treatment of HeLa cells with DOPAC-NCs affected the survival of irradiated cells in a dose-dependent manner. Our data demonstrate that cell survival of cells irradiated with 15 Gy and pre-treated with the highest concentration of DOPAC-NCs was as low as 23.7% compared to survival of cells that were not treated with DOPAC-NCs prior to irradiation. In opposite, without radiation, treatment with DOPAC-NCs had no effect on cell viability/proliferation. These findings provide in vitro evidence that DOPAC-NCs may be developed and employed as radiosensitizers in cervical cancer radiation therapy. Citation Format: Salida Mirzoeva, Beau M. Wanzer, Tatjana Paunesku, Gayle E. Woloschak. In vitro radiosensitization of human cervical cancer HeLa cells with iron oxide- titanium dioxide core-shell nanoparticles conjugated with 3,4-Dihydroxyphenylacetic acid (DOPAC). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5663. doi:10.1158/1538-7445.AM2013-5663